Keros Therapeutics (KROS)
(Delayed Data from NSDQ)
$46.04 USD
+2.67 (6.16%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $45.91 -0.13 (-0.28%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Keros Therapeutics, Inc. [KROS]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EHA Showcases Elritercept?s Continued Differentiation Across MDS and MF
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updates Across KER-050 and KER-012 Drive Investor Engagement; Reit. Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updates Across MDS, MF and PAH Programs Hold Multiple Value Inflection Points in ?24
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23: Poised to Generate Value in 2024/2025 w/Readouts Across the Pipeline
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Keros Throws its Hat into the Obesity Ring, Initial Ph1 KER-065 Data in Q1:25
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data at ASH ''23 Continue to Showcase KER-050?s Potential in MDS and MF; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ph2 Updates for KER-050 in MDS and MF @ ASH; Additional Data in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KROS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Updated Ph2 Results for KER-050 in MDS MF at ASH 2023
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KER-050 Set To Make A Splash During ASH?23; Reit. Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-The Wedbush Monthly Check-Up: November 2023
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KER-050''s MDS Market Opportunity Remains Despite REBLOZYL''s First-Line Approval
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Keros Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Keros'' Call on the Ph2 TROPOS Trial Design for KER-012/PAH
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A